Sandra Panchalingam

Sandra Panchalingam

Auto-generated profile, based on publicly available information

Sandra Panchalingam

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in The Lancet
Verified
Journal Article
Closed access
KKKaren L Kotloff
Karen L Kotloff
JNJames P Nataro
James P Nataro
WBWilliam C Blackwelder
William C Blackwelder
DNDilruba Nasrin
Dilruba Nasrin
TFTamer H Farag
Tamer H Farag
MLMyron M Levine
Myron M Levine

1 September 2016 in The Lancet
Verified
Journal Article
Closed access
JLJie Liu
Jie Liu
JPJames A Platts-Mills
James A Platts-Mills
JJJane Juma
Jane Juma
FKFurqan Kabir
Furqan Kabir
JNJoseph Nkeze
Joseph Nkeze
EHEric R Houpt
Eric R Houpt

23 June 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SLSofie Livio
Sofie Livio
NSNancy A. Strockbine
Nancy A. Strockbine
SPSandra Panchalingam
Sandra Panchalingam
STSharon M. Tennant
Sharon M. Tennant
EBEileen M. Barry
Eileen M. Barry
MLMyron M Max Levine
Myron M Max Levine
Shigella case isolates from the Global Enteric Multicenter Study were serotyped to guide vaccine development. A quadrivalent vaccine that includes O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 should provide broad protection. Background. Shigella, a major diarrheal disease pathogen worldwide, is the target of vaccine development. The Global Enteric Multicenter Study (GEMS) investigated burden and etiology of moderate-to-severe diarrheal disease in children aged <60 months and matched controls without diarrhea during 3 years at 4 sites in Africa and 3 in Asia. Shigella was 1 of the 4 most common pathogens across sites and age strata. GEMS Shigella serotypes are reviewed to guide vaccine development. Methods. Subjects' stool specimens/rectal swabs were transported to site laboratories in transport media and plated onto xylose lysine desoxycholate and MacConkey agar. Suspect Shigella colonies were identified by biochemical tests and agglutination with antisera. Shigella isolates were shipped to the GEMS Reference Laboratory (Baltimore, MD) for confirmation and serotyping of S. flexneri; one-third of isolates were sent to the Centers for Disease Control and Prevention for quality control. Results. Shigella dysenteriae and S. boydii accounted for 5.0% and 5.4%, respectively, of 1130 Shigella case isolates; S. flexneri comprised 65.9% and S. sonnei 23.7%. Five serotypes/subserotypes comprised 89.4% of S. flexneri, including S. flexneri 2a, S. flexneri 6, S. flexneri 3a, S. flexneri 2b, and S. flexneri 1b. Conclusions. A broad-spectrum Shigella vaccine must protect against S. sonnei and 15 S. flexneri serotypes/subserotypes. A quadrivalent vaccine with O antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 can provide broad direct coverage against these most common serotypes and indirect coverage against all but 1 (rare) remaining subserotype through shared S. flexneri group antigens.

15 December 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KKKaren L. Kotloff
Karen L. Kotloff
WBWilliam C. Blackwelder
William C. Blackwelder
DNDilruba Nasrin
Dilruba Nasrin
JNJames P. Nataro
James P. Nataro
TFTamer H. Farag
Tamer H. Farag
MLMyron M. Levine
Myron M. Levine
Background. Diarrhea is a leading cause of illness and death among children aged <5 years in developing countries. This paper describes the clinical and epidemiological methods used to conduct the Global Enteric Multicenter Study (GEMS), a 3-year, prospective, age-stratified, case/control study to estimate the population-based burden, microbiologic etiology, and adverse clinical consequences of acute moderate-to-severe diarrhea (MSD) among a censused population of children aged 0–59 months seeking care at health centers in sub-Saharan Africa and South Asia. Methods. GEMS was conducted at 7 field sites, each serving a population whose demography and healthcare utilization practices for childhood diarrhea were documented. We aimed to enroll 220 MSD cases per year from selected health centers serving each site in each of 3 age strata (0–11, 12–23, and 24–59 months), along with 1–3 matched community controls. Cases and controls supplied clinical, epidemiologic, and anthropometric data at enrollment and again approximately 60 days later, and provided enrollment stool specimens for identification and characterization of potential diarrheal pathogens. Verbal autopsy was performed if a child died. Analytic strategies will calculate the fraction of MSD attributable to each pathogen and the incidence, financial costs, nutritional consequences, and case fatality overall and by pathogen. Conclusions. When completed, GEMS will provide estimates of the incidence, etiology, and outcomes of MSD among infants and young children in sub-Saharan Africa and South Asia. This information can guide development and implementation of public health interventions to diminish morbidity and mortality from diarrheal diseases.

1 September 1997 in Immunity
Verified
Journal Article
Closed access
DLD.A. Lammas
D.A. Lammas
CSC. Stober
C. Stober
CHC.J. Harvey
C.J. Harvey
NKN. Kendrick
N. Kendrick
SPS. Panchalingam
S. Panchalingam
DKD.S. Kumararatne
D.S. Kumararatne

27 June 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
MPMihai Pop
Mihai Pop
AWAlan W Walker
Alan W Walker
JPJoseph Paulson
Joseph Paulson
BLBrianna Lindsay
Brianna Lindsay
MAMartin Antonio
Martin Antonio
OSO Colin Stine
O Colin Stine
Background: Diarrheal diseases continue to contribute significantly to morbidity and mortality in infants and young children in developing countries. There is an urgent need to better understand the contributions of novel, potentially uncultured, diarrheal pathogens to severe diarrheal disease, as well as distortions in normal gut microbiota composition that might facilitate severe disease. Results: We use high throughput 16S rRNA gene sequencing to compare fecal microbiota composition in children under five years of age who have been diagnosed with moderate to severe diarrhea (MSD) with the microbiota from diarrhea-free controls. Our study includes 992 children from four low-income countries in West and East Africa, and Southeast Asia. Known pathogens, as well as bacteria currently not considered as important diarrhea-causing pathogens, are positively associated with MSD, and these include Escherichia/Shigella, and Granulicatella species, and Streptococcus mitis/pneumoniae groups. In both cases and controls, there tend to be distinct negative correlations between facultative anaerobic lineages and obligate anaerobic lineages. Overall genus-level microbiota composition exhibit a shift in controls from low to high levels of Prevotella and in MSD cases from high to low levels of Escherichia/Shigella in younger versus older children; however, there was significant variation among many genera by both site and age. Conclusions: Our findings expand the current understanding of microbiota-associated diarrhea pathogenicity in young children from developing countries. Our findings are necessarily based on correlative analyses and must be further validated through epidemiological and molecular techniques.